Privia Health Group, Inc. (NASDAQ:PRVA) Shares Purchased by Benjamin Edwards Inc.

Benjamin Edwards Inc. boosted its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 44.9% in the 4th quarter, Holdings Channel reports. The firm owned 3,239 shares of the company’s stock after acquiring an additional 1,003 shares during the quarter. Benjamin Edwards Inc.’s holdings in Privia Health Group were worth $75,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Covestor Ltd boosted its holdings in shares of Privia Health Group by 8.3% during the 3rd quarter. Covestor Ltd now owns 6,703 shares of the company’s stock worth $154,000 after purchasing an additional 514 shares during the last quarter. International Assets Investment Management LLC boosted its stake in Privia Health Group by 2,721.7% during the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock worth $164,000 after buying an additional 6,886 shares during the last quarter. Assetmark Inc. grew its holdings in Privia Health Group by 17.6% in the 3rd quarter. Assetmark Inc. now owns 7,384 shares of the company’s stock valued at $170,000 after buying an additional 1,107 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Privia Health Group by 30.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 8,214 shares of the company’s stock valued at $189,000 after buying an additional 1,928 shares in the last quarter. Finally, Baron Wealth Management LLC acquired a new stake in shares of Privia Health Group in the 4th quarter worth $237,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling

In other Privia Health Group news, CFO David Mountcastle sold 3,933 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the transaction, the chief financial officer now owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Parth Mehrotra sold 12,219 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $225,073.98. Following the sale, the chief executive officer now directly owns 261,640 shares in the company, valued at $4,819,408.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David Mountcastle sold 3,933 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the sale, the chief financial officer now directly owns 262,279 shares in the company, valued at approximately $4,660,697.83. The disclosure for this sale can be found here. Insiders have sold a total of 31,783 shares of company stock valued at $582,886 in the last ninety days. Company insiders own 14.20% of the company’s stock.

Privia Health Group Trading Up 1.8 %

Shares of NASDAQ PRVA opened at $18.74 on Friday. The stock has a market capitalization of $2.22 billion, a PE ratio of 98.64, a PEG ratio of 2.56 and a beta of 0.81. Privia Health Group, Inc. has a twelve month low of $17.54 and a twelve month high of $30.15. The stock has a fifty day simple moving average of $19.62 and a 200-day simple moving average of $21.12.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $440.80 million for the quarter, compared to analysts’ expectations of $425.81 million. Privia Health Group had a net margin of 1.39% and a return on equity of 3.97%. The business’s revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 earnings per share. On average, equities analysts predict that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Barclays began coverage on shares of Privia Health Group in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price target on the stock. TD Cowen decreased their target price on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. JPMorgan Chase & Co. cut their price target on shares of Privia Health Group from $38.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 6th. UBS Group decreased their price objective on Privia Health Group from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, March 1st. Finally, Bank of America lowered Privia Health Group from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $27.00 to $21.00 in a research report on Thursday, February 22nd. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.62.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.